Beta Cell Function and BMI in Ethnically Diverse Children with Newly Diagnosed Autoimmune Type 1 Diabetes
Overview
Pediatrics
Authors
Affiliations
Objective: To examine the relationship between BMI and beta-cell function at diagnosis of autoimmune type 1 diabetes (T1D) in a large group of ethnically diverse children.
Methods: Cross-sectional analysis of 524 children (60.8% White, 19.5% Hispanic, 14.5% African-American, 5.2% other non-Hispanic; mean age = 9.8 yr [SD = 2.5]) with newly diagnosed autoimmune T1D.
Results: As much as 22.2% of children were overweight or obese. Median random serum C-peptide was 0.40 ng/mL (25th-75th percentiles = 0.3-0.8), with median glycemia of 366 mg/dL (25th-75th percentiles = 271-505). Median C-peptide was 0.3, 0.5, 0.7, and 0.85 ng/mL, respectively, in underweight, normal weight, overweight, and obese children (p < 0.0001, Kruskal-Wallis). In the final model (p < 0.0001), the odds of having preserved C-peptide (≥0.6 ng/mL) were increased by 2.4-fold (95% CI = 1.2-4.9, p < 0.015) and 4.1-fold (1.9-8.5, p < 0.0001), respectively, in overweight and obese compared to lean children; 1.3-fold per each year of age; 2.5-fold in girls compared to boys; 4-fold in children who presented without, compared to with, diabetes ketoacidosis (DKA); and decreased by 21% for each point increase in HbA1c. Tanner stage, race/ethnicity, glycemia, and number of anti-islet antibodies expressed were not independently associated with preserved C-peptide. The association between BMI and C-peptide levels was significant in children with and without preserved C-peptide. Excluding patients who presented with DKA and/or using BMI obtained 5 wk after diagnosis did not alter the results.
Conclusion: Obese and overweight children compared to lean children have greater beta-cell function at the onset of autoimmune T1D. Prospective studies on the relationships among BMI, beta-cell function, and progression to clinical T1D are warranted.
Cimbek E, Beyhun N, Karaguzel G Eur J Pediatr. 2025; 184(3):219.
PMID: 40025382 PMC: 11872750. DOI: 10.1007/s00431-025-06046-3.
Type 1 diabetes: immune pathology and novel therapeutic approaches.
Ling E, Lemos J, Hirani K, von Herrath M Diabetol Int. 2024; 15(4):761-776.
PMID: 39469552 PMC: 11512973. DOI: 10.1007/s13340-024-00748-z.
Al-Abdulrazzaq D, Qabazard M, Al-Jasser F, Al-Anizi A, Al-Basari I, Mandani F Med Princ Pract. 2024; 33(6):555-561.
PMID: 39097968 PMC: 11631037. DOI: 10.1159/000540705.
Gut Microbial Changes Associated With Obesity in Youth With Type 1 Diabetes.
Ismail H, Perera D, Mandal R, DiMeglio L, Evans-Molina C, Hannon T J Clin Endocrinol Metab. 2024; 110(2):364-373.
PMID: 39078977 PMC: 11747672. DOI: 10.1210/clinem/dgae529.
Jones A, Shields B, Oram R, Dabelea D, Hagopian W, Sharp S Diabetes Care. 2024; 47(12):2110-2119.
PMID: 38252849 PMC: 11655402. DOI: 10.2337/dc23-1815.